Welcome to our dedicated page for INVVY news (Ticker: INVVY), a resource for investors and traders seeking the latest updates and insights on INVVY stock.
Indivior PLC (LSE/Nasdaq: INDV) is a global pharmaceutical company dedicated to developing medicines to treat substance use disorders (SUD) and serious mental illnesses. With a vision to provide evidence-based treatments for chronic conditions worldwide, Indivior is focused on transforming SUD into a recognized and treated chronic disease. Headquartered in Richmond, VA, Indivior's portfolio of products is available in 37 countries, with a pipeline of product candidates aiming to address various chronic conditions and co-occurring disorders of SUD.
Indivior, a leading addiction treatment company, will host an analyst teach-in event in New York City, confirming its FY 2024 guidance. The company expects net revenue between $1,240m and $1,330m, an 18% increase from FY 2023. SUBLOCADE revenue is projected at $820m to $880m, a 35% rise. OPVEE revenue is anticipated to be $15m to $25m, and PERSERIS revenue is forecasted at $55m to $65m, a 43% increase. SUBOXONE Film market share is expected to decline by 1-2 percentage points. Adjusted gross margin is estimated to be in the low to mid-80s range.
Adjusted SG&A expenses are projected at $575m to $590m, with R&D expenses between $120m and $130m. Adjusted operating profit is expected to be $330m to $380m. The event will be webcast and aims to provide an in-depth overview of Indivior's growth and value creation strategies.
FAQ
What is the market cap of INVVY (INVVY)?
What does Indivior PLC specialize in?
Where is Indivior PLC headquartered?
How many countries is Indivior's portfolio of products available in?
What is Indivior's vision for patients around the world?
What is the focus of Indivior's global portfolio?
